ResMed to acquire MediFox-Dan for EUR 810M; closing expected by Dec 31, 2022

RESMED INC

Base purchase price of EUR 810M fixed via locked box; enterprise value EUR 950M.
Funded with existing cash and borrowings under credit facility; intercompany loan to ResMed Germany SaaS.
Closing subject to German merger control, foreign investment, and BaFin clearances.
Termination fee of EUR 10M payable to seller if BaFin clearance not obtained.
Acquisition of 100% of MediFox-Dan shares and shareholder loan receivables.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.